Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1

Patel, Dhaval; Balderes, Paul; Lahiji, Armin; Melchior, Maxine; Ng, Stanley; Bassi, Rajiv; Wu, Yan; Griffith, Heather; Jimenez, Xenia; Ludwig, Dale L.; Hicklin, Daniel J.; Kang, Xiaoqiang

doi:10.3233/hab-2007-163-407

Cited by 30 publications

(36 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2). The affinity constant ( K d ) was found to be similar for both the antibody and the ADC and comparable to the reported K d values, 26–28 suggesting that the conformational change, if any, is local and does not impact the antigen-binding domains of the antibody.…”

Section: Resultssupporting

confidence: 79%

Development of a facile antibody–drug conjugate platform for increased stability and homogeneity

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Resultssupporting

confidence: 79%

Development of a facile antibody–drug conjugate platform for increased stability and homogeneity

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A significant reduction in tumor load after CTA99 injection and an abolition of this effect after hFc␥RI blockade were also obtained in anti-Fc␥RIV mAb pretreated RAG-deficient hFc␥RI tg 5KO mice that cannot produce endogenous antibodies ( Figure 7D). Furthermore, injections of a fully human IgG1 mAb anti-TYRP-1 39 had a tendency to reduce tumor loads in hFc␥RI tg 5KO mice pretreated with anti-Fc␥RIV mAbs ( Figure 7E). Therefore, hFc␥RI mediates Ab-induced reduction of tumor load in transgenic mice after injection of humanized anti-TYRP-1 mAbs.…”

Section: Hfc␥ri Can Mediate Ab-induced Antitumor Immunotherapymentioning

confidence: 94%

The high-affinity human IgG receptor FcγRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy

Mancardi

Albanesi

Jönsson

et al. 2013

Blood

Self Cite

127

112

View full text Add to dashboard Cite

Key Points• Human Fc␥RI can trigger antibody-induced inflammatory arthritis, thrombocytopenia, airway inflammation, and systemic anaphylaxis.• Human Fc␥RI can trigger antibody-mediated immunotherapy of mouse metastatic melanoma.Receptors for the Fc portion of IgG (Fc␥Rs) are mandatory for the induction of various IgG-dependent models of autoimmunity, inflammation, anaphylaxis, and cancer immunotherapy. A few Fc␥Rs have the ability to bind monomeric IgG: high-affinity mouse mFc␥RI, mFc␥RIV, and human hFc␥RI. All others bind IgG only when aggregated in complexes or bound to cells or surfaces: low-affinity mouse mFc␥RIIB and mFc␥RIII and human hFc␥RIIA/B/C and hFc␥RIIIA/B. Although it has been proposed that high-affinity Fc␥Rs are occupied by circulating IgG, multiple roles for mFc␥RI and mFc␥RIV have been reported in vivo. However, the potential roles of hFc␥RI that is expressed on monocytes, macrophages, and neutrophils have not been reported. In the present study, we therefore investigated the role of hFc␥RI in antibody-mediated models of disease and therapy by generating hFc␥RI-transgenic mice deficient for multiple endogenous FcRs. hFc␥RI was sufficient to trigger autoimmune arthritis and thrombocytopenia, immune complex-induced airway inflammation, and active and passive systemic anaphylaxis. We found monocyte/macrophages to be responsible for thrombocytopenia, neutrophils to be responsible for systemic anaphylaxis, and both cell types to be responsible for arthritis induction.

show abstract

“…First, we studied a time course of neutrophil infiltration after administration of TA99. 24 and 48 h after the administration of TA99 at 40 mg/kg, [8] we collected mouse tumor tissues and performed the flow cytometry after staining with Alexa-Fluor-488-labeled anti-mouse Gr-1 to mark neutrophils. It is noted that the infiltration of neutrophils in tumor tissues was strongly dependent on TA99, and the percentage of neutrophils dramatically increased 48 h after the administration of TA99 (Figure 1A and S4A–S4D), suggesting that TA99 can facilitate the infiltration of neutrophils into tumor, which is consistent with the previous study.…”

Section: Antibody Increases the Accumulation Of Nps In Tumor Mediatedmentioning

confidence: 99%

“…[6] In a mouse model of B16 melanoma, it is found that monoclonal antibody TA99 specific for gp75 antigen can induce neutrophil recruitment in tumor sites as a mechanism of antibody-dependent cell-mediated cytotoxicity (ADCC) for cancer therapy, and neutrophils are a major component of ADCC effect rather than other immune effector cells. [7, 8] The interaction of neutrophils with tumor cells is mediated by the binding of antibody Fc portion to Fc receptors expressed on immune cells. [9] Targeting neutrophils in vivo using NPs could enhance the delivery of drugs in the tumor microenvironment.…”

mentioning

confidence: 99%

Nanoparticle Targeting of Neutrophils for Improved Cancer Immunotherapy

Zhao²,

et al. 2016

Adv Healthcare Materials

114

102

View full text Add to dashboard Cite

Cancer immunotherapy using tumor specific monoclonal antibodies (mAbs) presents a novel approach for cancer treatment. A monoclonal antibody TA99 specific for gp75 antigen of melanoma, initiates neutrophil recruitment in tumor responsible for cancer therapy. Here we report a strategy for hijacking neutrophils in vivo using nanoparticles (NPs) to deliver therapeutics into tumor. In a mouse model of melanoma, we showed that systemically delivered albumin NPs increased in tumor when TA99 antibody was injected; and the nanoparticle tumor accumulation was mediated by neutrophils. After the administration of pyropheophorbide-a (Ppa) loaded albumin NPs and TA99, photodynamic therapy significantly suppressed the tumor growth and increased mouse survival compared with treatment with the NPs or TA99. The study reveals a new avenue to treat cancer by nanoparticle hitchhiking of immune systems to enhance delivery of therapeutics into tumor sites.

show abstract

Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1

Cited by 30 publications

References 0 publications

Development of a facile antibody–drug conjugate platform for increased stability and homogeneity

Development of a facile antibody–drug conjugate platform for increased stability and homogeneity

The high-affinity human IgG receptor FcγRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy

Nanoparticle Targeting of Neutrophils for Improved Cancer Immunotherapy

Contact Info

Product

Resources

About